McGill University Health Centre

Heritage MD donates $500K to the MUHC Foundation to fund innovation at the McGill University Health Centre

Retrieved on: 
水曜日, 5月 29, 2024
McGill University Health Centre, MUHC, DNA, Québécois people, Drive, Heritage, Heritage Council (Ireland), Dream, Trust, Research, Physician, Research institute, Infection, Cardiology, Pharmaceutical industry

This gift underscores Heritage MD’s commitment to supporting the McGill University Health Centre and the Research Institute of the MUHC and fostering collaborations that will positively impact lives nationwide.

Key Points: 
  • This gift underscores Heritage MD’s commitment to supporting the McGill University Health Centre and the Research Institute of the MUHC and fostering collaborations that will positively impact lives nationwide.
  • At the helm of the Heritage Council stands Dr. Renzo Cecere, a distinguished Cardiac Surgeon at the MUHC, past Chief of Cardiac Surgery and former Chair of the McGill University Health Centre (MUHC) Physicians Council.
  • Both Heritage MD and the MUHC Foundation are fundamentally driven by the mission of championing health care professionals and fostering innovation within Quebec's health care sector.
  • “We are so grateful for Heritage MD’s generosity and appreciate their commitment to supporting local health care through the MUHC Foundation.

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
月曜日, 5月 20, 2024
Insurance, Patient, Hepatectomy, Liver disease, PMDA, Marketing, McGill University Health Centre, Colorectal cancer, KPC, Clinical trial, Neoplasm, Government, D&O, Head, Safety, Alpha Sigma Tau, Congress, Pancreatic cancer, Brain, Carcinoma, Rambam Health Care Campus, Lung cancer, Alpha, G&A, Liver cancer

JERUSALEM, May 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2024 financial results and provided a corporate update.

Key Points: 
  • Alpha Tau anticipates remaining adequately capitalized to support all of these programs over the coming years," he concluded.
  • In May, preclinical data demonstrating an abscopal immune effect in pancreatic murine tumor models was presented at ESTRO 2024 Congress in Glasgow.
  • Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone.
  • Targeting completion of patient recruitment in the ReSTART U.S. multi-center pivotal trial in recurrent cutaneous squamous cell carcinoma in H2 2024.

The Doggone Foundation donates $150K to the MUHC Foundation to support breast cancer research

Retrieved on: 
水曜日, 5月 15, 2024
McGill University Health Centre, MUHC, Patient, DNA, Liquid biopsy, Doggone, Science, Recurrence, Disease, Liquid, Breast cancer, Blood, Research, Face, Cancer, Breast, Glen, Medicine, Woman, Medical imaging

“We are on the precipice of major, life-changing breakthroughs in breast cancer research, and the Doggone Foundation is happy to champion the research taking place at the MUHC.

Key Points: 
  • “We are on the precipice of major, life-changing breakthroughs in breast cancer research, and the Doggone Foundation is happy to champion the research taking place at the MUHC.
  • Our gift to the MUHC Foundation underscores our belief in the MUHC’s researchers who will change the face of this cancer.
  • “The MUHC Foundation is grateful to the Doggone Foundation for their ongoing generosity and support of our mission to advance cancer care in Quebec.
  • The impact of this donation towards discovering a breast cancer signature cannot be overstated; it marks an exciting moment in precision cancer research.

Adagio Medical Announces First European Commercial Procedures and Commencement of U.S. FDA Pivotal IDE for Ventricular Tachycardia Cryoablation System

Retrieved on: 
木曜日, 5月 16, 2024
Medical Devices, FDA, Health, Hospitals, Surgery, Cardiology, McGill University Health Centre, Partnership, Patient, Arrhythmia, E pluribus unum, Food, EFS, Atrial flutter, Disease, Safety, Tachycardia, Ventricular tachycardia, Electrophysiology, Catheter, Catheter ablation, Atrial fibrillation, Division, PVC, Medicine, Endocardium, Console, Medical device

Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration (“FDA”) approval of the FULCRUM-VT Pivotal IDE study of the VT Cryoablation System.

Key Points: 
  • Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration (“FDA”) approval of the FULCRUM-VT Pivotal IDE study of the VT Cryoablation System.
  • That data, in combination with the Cryocure-VT dataset support FDA approval for the conversion of the FULCRUM-VT study to pivotal phase.
  • The vCLAS™ Cryoablation Catheter, a component of the Adagio Medical, Inc. VT Cryoablation System is intended to create transmural linear and focal lesions to cardiac structures within the endocardium of the ventricles with cryoablation.
  • Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies.

New Findings in JNCCN Illustrate Pathway for Screening High-Risk Individuals for Pancreatic Cancer in PRECEDE Study

Retrieved on: 
火曜日, 4月 16, 2024
University, Clinical trial, NCCN, Pancreas, McGill University Health Centre, Risk, Pancreatic cancer, Breast, Prevalence, Cancer, National Comprehensive Cancer Network, Rosalind, Survival, Survival rate, Cyst, Doctor of Philosophy, Huntsman Cancer Institute, Research, Moores Cancer Center, Consortium, Disease, Incidence, Patient, Pancreatic Cancer Action Network, Diagnosis, Research institute, PGV, Dana–Farber Cancer Institute, Morávek, UC, McGill University, Pharmaceutical industry

PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer. Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%. When pancreatic neoplasms are detected early enough for treatment with surgical resection, the survival rate climbs to better than 80%, but unfortunately the vast majority of patients are diagnosed with advanced-stage disease. The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease. Of 1,759 participants sorted into the highest-risk cohort, nearly 80% completed baseline imaging through PRECEDE.

Key Points: 
  • Global incidences of pancreatic cancer have risen dramatically in recent years, but the overall survival rate is currently only 12%.
  • The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a global effort to increase screening capacity for this disease.
  • "I look forward to further research... to improve access to pancreatic cancer screening for high-risk individuals."
  • "Longer follow-up time is needed to determine if familial pancreatic cancer signifies a higher risk for developing pancreatic cancer compared to pathogenic germline variant (PGV) status in a pancreatic cancer predisposition gene."

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

Retrieved on: 
火曜日, 4月 9, 2024
Neurology, University college, Patient, McGill University Health Centre, Head, Doctor of Philosophy, MDCM, OPMD, Otorhinolaryngology, Natural history

To register, click here .

Key Points: 
  • To register, click here .
  • The event will feature two key opinion leaders who will discuss the clinical symptoms and the natural history of oculopharyngeal muscular dystrophy (OPMD), a rare genetic muscle disorder.
  • The key opinion leaders will also review the clinical and radiographic methods employed to evaluate disease progression and discuss the current treatment landscape for patients diagnosed with OPMD.
  • A live question and answer session will follow the formal presentations.

Kardium Announces Completion of Paroxysmal Enrollment in the PULSAR IDE Study

Retrieved on: 
火曜日, 4月 2, 2024
Software, Hardware, Medical Devices, Technology, Health Technology, Clinical Trials, Surgery, Nanotechnology, Cardiology, Biotechnology, FDA, Health, Inc., Atrial fibrillation, Patient, Gold, PFA, McGill University Health Centre, IDE, Electrode, Workflow, Heart, PMA, Safety, Patient safety, Multimedia, Mount Sinai Hospital, Food, Medical device

Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.
  • (Photo: Business Wire)
    The PULSAR IDE study, an international, multi-center clinical trial, is designed to evaluate the safety and effectiveness of the Globe System for the treatment of atrial fibrillation.
  • The successful completion of enrollment underscores the commitment of the clinical sites, investigators, and the entire Kardium team.
  • "The completion of enrollment in the PULSAR study represents a major accomplishment for Kardium.

Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers

Retrieved on: 
月曜日, 3月 25, 2024
CE marking, Temperature, Electrophysiology, Atrial fibrillation, Patient, Journal, Ventricular tachycardia, Science, McGill University Health Centre, MD, CCB, Tachycardia, Catheter ablation, Division, Arrhythmia, Catheter, Adagio, Medical device

The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLAS™ ventricular cryoablation catheter ("vCLAS").

Key Points: 
  • The system consists of the upgraded cryoablation console, also capable of supporting atrial ablation procedures using commercially available iCLAS™ catheters, and the vCLAS™ ventricular cryoablation catheter ("vCLAS").
  • The system will be featured at the upcoming conference of the European Heart Rhythm Association ("EHRA") in Berlin on April 7-9, 2024 and will become immediately available for clinical use in select European centers.
  • Unlike conventional radiofrequency ("RF") catheters commonly used for both ventricular and atrial procedures, the 9Fr, bi-directional deflectable vCLAS catheter was designed specifically to address the challenges of VT ablations.
  • CE Mark approval for the vCLAS catheter has been granted based on the results of the Cryocure-VT trial, which enrolled patients with monomorphic VT of both ischemic and non-ischemic origin at nine European and Canadian centers.

Proton beam therapy: A modern treatment for cancer, but not in Canada (yet)

Retrieved on: 
火曜日, 2月 6, 2024
Proton, Partnership, Meal, Proton therapy, Travel, Pelvis, Deficit spending, Prostate, Patient, G7, Brain, Spine, Medulloblastoma, McGill University Health Centre, Tissue, Cancer, Abdomen, Ability, Disease, Medical imaging

Proton beam therapy is a more precise treatment that can better focus radiation on a cancer, reducing the side-effects of treatment.

Key Points: 
  • Proton beam therapy is a more precise treatment that can better focus radiation on a cancer, reducing the side-effects of treatment.
  • This leads to better cognitive function and fewer long-term side-effects among patients who receive proton therapy compared to X-ray (photon) treatment.
  • Although proton therapy is more expensive to deliver than photon radiation, studies have shown long-term cost-effectiveness of proton beam therapy for medulloblastoma.
  • In a study of more than 1,000 adults with other types of locally advanced cancer, proton therapy led to fewer unplanned hospitalizations.

Canadian patients need to travel for treatment

  • Researchers in the U.K. estimate that up to 15 per cent of all patients with curable cancers may benefit from proton therapy.
  • However, without a domestic facility, Canadians who need proton beam therapy must travel out-of-country to receive this medically necessary treatment for their cancer.


Patients who are able to travel out-of-country report high levels of stress and feelings of isolation. Many of these concerns would be reduced with a domestic, Canadian proton therapy facility.

Progress toward Canadian facilities


In 2016, Québec announced a partnership with a private health-care company to build a standalone proton therapy facility in Montréal.

  • It is recognized that the per-patient cost to deliver proton therapy would be less if a Canadian facility were available.
  • Canadian doctors and patients eagerly await the day when a cancer patient can receive this advanced treatment without travelling out of country.
  • Having access to proton therapy would also allow Canadian researchers to collaborate globally in scientific studies.


Derek Tsang receives research grant funding from ACCESS (https://accessforkidscancer.ca), the Brain Tumour Foundation of Canada, and the US National Cancer Institute. Tsang also received travel funding from Mevion Medical Systems in 2022.

Minister St-Onge announces the appointment of Cynthia Price Verreault as the next Chairperson of the Canadian Museum of Immigration at Pier 21

Retrieved on: 
金曜日, 2月 2, 2024
Diamond, Science, Chairperson, The, The Act, Commerce, Pier, Queen Elizabeth, McGill University Health Centre, McGill University, Trustee, Museum, Organization, Furniture

Recently appointed Governor Emerita of McGill University, Ms. Price Verreault has served on several of its advisory committees.

Key Points: 
  • Recently appointed Governor Emerita of McGill University, Ms. Price Verreault has served on several of its advisory committees.
  • The Canadian Museum of Immigration at Pier 21 is a national museum in the Canadian Heritage portfolio.
  • The Canadian Museum of Immigration at Pier 21 is a national museum whose mandate is to enhance public understanding of the experience of immigrants as they arrived in Canada.
  • Under the Act, the Chairperson is appointed by the Minister of Canadian Heritage, with the approval of the Governor in Council.